Hepatitis B Vaccination Clinical Trial
Official title:
Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users: a Randomized, Controlled Trial
Uptake, adherence, and completion of vaccination among drug users were low, and their immune function and immune response to hepatitis B vaccination were also suboptimal, indicating that the current practice of hepatitis B vaccination can't protect drug users from HBV infection. This is a randomized, open-label, blank-controlled trial, conducted among drug users with drug rehabilitation. This study will compare the immunogenicity and safety of three intramuscular 20µg and 60µg recombinant hepatitis B vaccines at months 0, 1, and 6 among drug users
Comparison of 2 vaccination strategy against Hepatitis B in Drug Users Intervention: Arm 1 : Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6; Arm 2 : Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6; Arm 3 : Receive no vaccination during the study period. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05787899 -
Hypothermia's Effect on Hepatitis B Vaccination
|
||
Completed |
NCT04162223 -
Hepatitis B Vaccine in Seniors
|
Early Phase 1 | |
Terminated |
NCT02166671 -
Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years
|
N/A |